← boothcheck

Is RXO overvalued?

boothcheck doesn't label RXO overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, RXO is priced for today's economics sustained for about 19 years. The price is justified by relative-multiple and growth-DCF; asset-based land below the price. The more the price assumes beyond what RXO, INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from RXO, INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 28, 2026.

Implied growth
For about19 yrs
Margin needed
Margin today-1.1%
Price vs asset value3.22x
Price vs peer multiples0.53x
Price vs forward growth0.91x
Read the full RXO report →
Get boothcheck's read on what RXO's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.